Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "PALONOSETRON HYDROCHLORIDE INJECTION" PASSES CONSISTENCY EVALUATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"PALONOSETRON HYDROCHLORIDE INJECTION"

PASSES CONSISTENCY EVALUATION

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company", together with its subsidiaries, the "Group") announces that "Palonosetron Hydrochloride Injection" (Product name "Zhiruo") (specifications: 5ml: 0.25mg and 1.5ml: 0.075mg), a drug developed by the Group, for the prevention of nausea and vomiting caused by chemotherapy has obtained the notice of approval of supplemental application on pharmaceutical product issued by the National Medical Products Administration of the People's Republic of China, and passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs.

Palonosetron hydrochloride is a second-generation5-HT3 receptor antagonist with a highly selective antagonistic effect on 5-HT3 receptors, reducing the incidence of nausea and vomiting, and is currently the only 5-HT3 receptor antagonist approved for the prevention of late-onset malignant vomiting. Compared with other 5-HT3 antagonists, palonosetron hydrochloride has the advantage of a long half- life and strong affinity to the receptor. With its good efficacy and safety, palonosetron hydrochloride has become a common drug for clinical prevention of chemotherapy-induced nausea and vomiting.

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 13 May 2021

As at the date of this announcement, the Board of the Company comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five Independent Non- Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Mr. Li Kwok Tung Donald.